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AbstrACt
Introduction Vasopressin stimulates cyst growth in 
autosomal dominant polycystic kidney disease (ADPKD) 
leading to enlarged kidneys, hypertension and renal failure. 
Vasopressin receptor blockade slows disease progression. 
Physiological suppression of vasopressin secretion through 
high water (HW) intake could achieve a similar effect, 
necessitating a definitive large-scale trial of HW intake in 
ADPKD. The objective of the DRINK trial is to answer the 
key design and feasibility questions required to deliver a 
successful definitive water intake trial.
Methods and analysis We describe the design of a single-
centre, open-label, prospective, randomised controlled trial. 
The "Determining feasibility of r andomisation to high vs. 
ad libitum water In take in Polycystic K idney Disease" 
(DRINK) trial aims to enrol 50 patients with ADPKD, over 
the age of 16 years with an estimated glomerular filtration 
rate (eGFR) ≥20 mL/min/1.73 m2. Participants will be 
randomised 1:1 to HW intake based on an individualised 
water intake prescription, or to ad libitum (AW) water 
intake. The HW group will aim for a dilute urine (urine 
osmolality ≤270 mOsm/kg) as a surrogate marker of 
vasopressin suppression, and those in the AW group will 
target more concentrated urine. Participants will have an 
8-week treatment period, and will be seen at weeks 0, 
2, 4 and 8, undergoing assessments of fluid status, renal 
function and serum and urine osmolalities. They will receive 
dietary advice, and self-monitor urine specific gravity and 
fluid intake. The trial employs smartphone technology to 
permit home monitoring and remote direct data capture. 
The primary feasibility end points are recruitment rate and 
separation between arms in measured urinary osmolality. 
Key secondary assessments include acceptability, 
adherence, health-related quality of life, acute effects of 
HW intake on measured (51Cr-EDTA) and eGFR and ADPKD-
related pain.
Ethics and dissemination Ethical approval was awarded 
by the East of England Essex Research Ethics Committee 
(16/EE/0026). The results of DRINK will be submitted to 
peer-reviewed journals, and presented to patients via the 
PKD Charity.
trial registration number NCT02933268 and 
ISCRTN16794957
IntroDuCtIon
Autosomal dominant polycystic kidney 
disease (ADPKD) is the the most common 
human inherited renal disorder affecting 
12 million people worldwide.1 Kidney cyst 
growth throughout the life span leads to 
enlarged kidneys, hypertension and impaired 
kidney function. More than two-thirds of 
those affected will develop kidney failure by 
a median age of 58 years,2 approximately 10 
strengths and limitations of this study
 ► The use of a randomised controlled feasibility trial 
designed to determine adherence and adequate 
separation between treatment arms will provide 
crucial data on the practical and biological feasibility 
of a definitive global high water trial.
 ► Self-monitoring and recording of results using 
smartphone technology will aid compliance and 
allow remote data capture, thereby reducing the 
burden of trial visits on participants and facilitate 
recruitment and streamlining of future trials.
 ► The effect of high water intake in autosomal dom-
inant polycystic kidney disease (ADPKD) was iden-
tified as a research priority by patients with ADPKD 
. The trial was designed and is being conducted in 
partnership with the PKD Charity.
 ► DRINK will include those with more advanced kidney 
disease (chronic kidney disease (CKD)3 and CKD4), 
representative of typical patients under hospital 
care.
 ► DRINK is limited by the relatively short duration of 
follow-up, thus not providing data on the long-term 
sustainability of fluid prescription adherence.
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years earlier than for most other primary kidney diseases.3 
Interventions that slow the progression of ADPKD are 
urgently needed.
ADPKD is usually caused by mutations in PKD1, PKD2 
or, rarely, GANAB.4 Its pathogenesis is incompletely 
understood. PKD1 and PKD2 encode the polycystins 
PC1 and PC2, respectively. PKD1 or PKD2 mutations lead 
to reductions in intracellular calcium, accumulation and 
impaired destruction of cyclic adenosine monophosphate 
(cAMP) and reduced intracellular ATP. This promotes 
sensitivity of collecting duct epithelial cells for the tonic 
effects of vasopressin.5 Since vasopressin promotes 
cyst growth, it has emerged as a therapeutic target for 
ADPKD.6 Recent evidence has confirmed efficacy of vaso-
pressin receptor blockade with the V2 receptor antagonist 
Tolvaptan in slowing ADPKD progression, reducing the 
annual increase in total kidney volume (TKV) by 2.7%7 
and slowing the rate of estimated glomerular filtration 
rate (eGFR) decline.8 However, the utility of Tolvaptan is 
limited by cost and side effects, with up to 25% of patients 
intolerant of the drug.7
Vasopressin release from the posterior pituitary is 
driven by plasma osmolality,9 and is readily suppressed by 
drinking beyond thirst. It is therefore plausible that high 
water (HW) intake could slow the progression of ADPKD 
through reduced exposure of the kidneys to vasopressin. 
Congruent with this hypothesis, studies in the PCK rat have 
shown slowing of cystic kidney disease and vasopressin 
suppression with HW consumption.10 11 In humans, Amro 
et al12 showed significant reductions in copeptin concen-
tration and urine osmolality after 2 weeks of solute restric-
tion and HW intake in 34 patients with ADPKD. In a 
prospective observational study, HW intake in 13 patients 
with ADPKD resulted in reduced urine osmolality and 
increased urine volume compared with healthy controls 
after 7 days13. However, in a non-randomised prospective 
study of 30 patients with ADPKD, HW intake resulted 
in a more rapid decline in eGFR and increase in TKV 
despite a significant reduction in urine osmolality and 
plasma copeptin level compared with controls.14 Uncer-
tainty therefore remains over the effectiveness and safety 
of HW intake in preserving kidney function in patients 
with ADPKD. Adequately powered randomised trials are 
urgently needed.
One other trial of HW intake is currently underway 
(PREVENT-ADPKD ACTRN12614001216606), with 
the aim of recruiting 180 patients with ADPKD who 
will be randomised to HW or standard water intake.15 
However, PREVENT-ADPKD has several important 
limitations. First, patients with eGFR <30 mL/min are 
excluded from the trial. Second, the primary outcome 
is change in height-adjusted TKV (htTKV), a surrogate 
for kidney function decline. Powered (87%) to detect a 
relatively large difference in htTKV increase, there is a 
very real risk that clinically meaningful effect may exist 
but might not be detected in a trial of this size. Third, 
the validity of htTKV as a surrogate for disease progres-
sion is disputed.7 16 PREVENT-ADPKD will therefore not 
determine the effect of HW intake on kidney function. 
Finally, PREVENT-ADPKD will not assess the acute effects 
of increased hydration in eGFR. Acute effects are of high 
importance in selecting the most appropriate kidney 
function end point for interventional trials in CKD.17 It is 
apparent that, irrespective of the outcome of this trial, a 
large randomised comparison of the effect of HW intake 
versus standard of care on kidney function will remain 
necessary.
We report the design and set-up of a randomised feasi-
bility trial of HW versus ad libitum (AW) water intake, 
developed to rigorously assess the feasibility of a definitive 
trial powered to detect a difference in kidney function 
decline in patients with ADPKD. This trial was initiated by 
patient members of the PKD Charity through a research 
proposal to the Patient Led Research Hub during 2016, 
and has been codesigned and produced (and part 
funded) by the PKD Charity. A full version of the trial 
protocol can be found at the following link http:// cctu. 
medschl. cam. ac. uk/ Trials/ Drink/ Materials. htm on the 
DRINK trial website.
MEthoDs AnD AnAlysIs
objectives
The primary feasibility objectives are: 1) recruitment rate 
and 2) achievement of target urine osmolality in ≥85% of 
study participants in the HW group. Secondary end points 
include separation in urine osmolality between trial 
arms, the completeness of self-monitored urine specific 
gravity (uSG) data (adherence to the self-monitoring 
regimen), serious adverse event rate, changes in quality 
of life using the EuroQol Five Dimensions (EQ5D) scores 
from baseline to 8 weeks, change in pain scores between 
groups, change in measured GFR between baseline and 4 
weeks and change in eGFR between baseline and 4 weeks 
(box 1).
trial design
This prospective, open-label, randomised trial was 
designed to assess the feasibility of a large definitive 
randomised controlled trial comparing the effective-
ness and safety of HW intake in patients with ADPKD 
with a control arm of AW water intake. Participants were 
randomly assigned (1:1) to receive either a prescribed 
(high) fluid intake sufficient to achieve vasopressin 
suppression, or to AW water intake (figure 1). Following 
an 8-week treatment period where participants will under-
take all the trial assessments, they will undergo a 4-week 
washout and have one final end of trial visit at week 12. 
The trial was first proposed by the PKD Charity, and was 
developed through and supported by the Cambridge 
Patient Led Research Hub, and run by the Cambridge 
Clinical Trials Unit.
Two nested substudies will be conducted: 1) substudy 
A includes 51CR-EDTA measured GFR and is designed 
to assess the acute effects on GFR of HW intake in the 
HW group. This substudy aims to enrol a minimum of 
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eight participants; 2) substudy B is designed to assess the 
impact of a novel smartphone-based fluid intake moni-
toring device (termed SPLASH)18 in promoting adher-
ence to fluid prescriptions (figure 2). Substudy B aims to 
enrol at least 10 participants.
trial population, eligibility criteria and recruitment
Patients with a confirmed diagnosis of ADPKD aged 
16 years or older are eligible for enrolment in the trial 
(box 2). Patients are deemed ineligible if they have 
advanced renal impairment (defined as an eGFR <20 mL/
min/1.73 m2), are unable to provide informed consent, 
are unable or unwilling to comply with study proce-
dures including self-monitoring of uSG, have evidence of 
fluid excess (defined as peripheral oedema, pulmonary 
oedema, heart failure, liver cirrhosis) or are receiving 
treatment with diuretics for such states, have concomi-
tant renal diseases other than ADPKD, are pregnant or 
breast feeding or are receiving treatment with Tolvaptan 
within 4 weeks of screening.
In this single-centre trial, participants will be recruited 
from the renal genetics and tubular disorders clinic at 
Addenbrooke’s Hospital, Cambridge. Patients from other 
centres are eligible for entry, but have to attend Adden-
brooke’s Hospital for screening, enrolment and study 
procedures. Patients will be reimbursed for travel and 
other expenses, but will not receive any other payment or 
incentives for trial participation.
The DRINK trial was advertised nationally on the 
PKD Charity and RaDAR websites and presented at PKD 
Patient Information days. Recruitment commenced in 
September 2016. The trial aims to enrol up to 50 partic-
ipants. The trial steering committee may recommend 
halting recruitment at any point after 30 patients have 
been enrolled if it is clear that the feasibility questions 
have been adequately addressed.
randomisation
Participants will be randomly assigned (1:1) to HW or 
AW water intake using a manual sealed envelope system 
prepared by the Cambridge Clinical Trials Unit statisti-
cian and to which the trial team will be blinded.
Although we have chosen patient level randomisation, 
the autosomal dominant inheritance pattern of ADPKD 
box 1 DrInK trial primary and secondary end points
Primary end points
 ► The number of patients eligible for, and randomised to the trial
 ► The proportion of patients in the high water intake group achieving 
a urine osmolality <270 mOsm/kg
secondary end points
 ► The proportion in each of the high and ad libitum water intake groups 
achieving their target urine osmolality (between-group separation)
 ► The proportion of participants that can self-monitor and report urine 
SG reliably
 ► Acceptability and usability of the SPLASH app (qualitative question-
naires and interviews)
 ► Incidence of serious adverse events
 ► Change between baseline and 8  weeks in quality of life scores 
(measured using EQ5D)
 ► Change between baseline and 8wk pain scores (measured using 
Pain Questionnaire)
 ► Change in measured glomerular filtration rate  (GFR) between base-
line and 4 weeks (acute GFR effects in high water intake group)
 ► Change in estimated GFR between baseline and 4 weeks (both 
groups)
 ► Acute GFR effects measured as the change in 51CR-EDTA measured 
GFR from week 0 to week 4
Figure 1 Schematic of the DRINK trial design. Participants are randomised 1:1 to the high water (HW) or ad libitum (AW) water 
intake groups. Each participant in the HW group is given an individualised daily water prescription with urinary dilution targets 
consistent with vasopressin suppression. The AW group has more concentrated urinary targets. ADPKD, autosomal dominant 
polycystic kidney disease; uSG, urine specific gravity.
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raises the particular challenge that multiple members 
of the same family or household may participate in 
a trial. In the context of HW intake, this may result in 
contamination between trial arms since fluid consump-
tion patterns of one family member may be influenced 
by that of another. This is particularly relevant given that 
we have previously reported that up to 80% of patients 
with ADPKD regularly discuss their condition and treat-
ments with their family members.19 The ability to draw 
inferences on contamination between trial arms within 
family clusters will be dependent on the number of 
related participants enrolled into the trial. Were contami-
nation between arms apparent within family clusters, this 
may need to be taken into account in the randomisation 
strategy for a definitive trial.
Intervention
Participants allocated to the HW intake arm will receive 
an individualised daily fluid intake prescription based on 
the free water clearance formula (figure 3) and designed 
to achieve suppression of vasopressin.
The fluid prescription will be titrated to response against 
uSG (table 1), since a uSG ≤1.010 correlates with vaso-
pressin suppression and is easily assessable by urine indi-
cator strip testing.20 Urine osmolality will also be measured 
during study visits, and fluid prescription titrated in order 
to achieve a urine osmolality of ≤270 mOsm/kg. Partic-
ipants are required to self-monitor uSG twice weekly to 
ensure that their fluid intake is sufficient to maintain the 
dilution target. Remote monitoring of home uSG values 
will be facilitated through the use of a bespoke smart-
phone application (app) that allows participants to input 
and monitor their uSG values. Titration instructions are 
embedded within the app. Participants will be encour-
aged to preferentially consume water, but consumption 
of other beverages is not restricted and will contribute to 
calculation of the daily fluid consumption total. Partic-
ipants will undergo regular dietary evaluation encour-
aging them to maintain moderate sodium (<2 g/day) and 
protein (0.75–1 g/kg/day) intake in order to facilitate 
adherence to the urinary dilution target.
Figure 2 Smartphone technology used during the DRINK study. The SPLASH app uses near field communication technology 
to automate fluid intake monitoring (left). The DRINK app will be used to record urine specific gravity results allowing remote 
data collection and monitoring of progress (right).
box 2 Eligibility criteria
Inclusion criteria
Diagnosis of autosomal dominant polycystic kidney disease (radiologi-
cal and or genetic evidence of PKD1 or PKD2 mutations)
Aged 16 years or older
Ability to provide informed consent estimated  glomerular filtration 
rate ≥20 mL/min/1.73 m2
Able to self-monitor urine specific gravity
Exclusion criteria
Fluid overload states, eg, heart failure, cirrhosis or requirement for fluid 
restriction
Confounding illness impacting on renal disease, eg, concomitant diabe-
tes or glomerulonephritis
Treatment with diuretics for fluid overload (those on diuretics for hy-
pertension may participate in the trial after a run-in period of 2 weeks)
Treatment with Tolvaptan in the last 4 weeks
Pregnancy or breast feeding
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Control
Participants allocated to the AW arm will not be given any 
fluid intake target, but will be asked to drink according 
to their usual practice and guided by thirst. They will 
also be required to monitor uSG using as for the HW 
group, but with a uSG target of >1.010 (corresponding 
to a urine osmolality >300 mOsm/kg) given that, above 
this threshold, vasopressin is not suppressed. If the uSG 
is below this threshold, fluid intake is to be titrated to 
achieve the target (table 1), requiring a reduction in fluid 
intake. Dietary advice will be as for the HW group.
Adherence
Any attempt to conduct a trial of HW intake will need to 
identify mechanism for, and demonstrate the feasibility 
of, achieving and maintaining separation between trial 
arms sufficient to realistically translate into a biologically 
meaningful effect. Studies of the effect of HW intake 
advice on renal stone disease have shown the majority 
of patients are non-adherent to fluid prescription21 and, 
in patients with ADPKD,19 often overestimate daily fluid 
intake. Several methods have been used to increase 
water intake in adults including education and coun-
selling, goal setting, self-monitoring or the provision of 
calibrated containers. A recent systematic review of 16 
studies showed that self-monitoring (urine volume and 
uSG) were the most effective strategy to increase fluid 
intake, highlighting the importance for adherence-pro-
moting methods.21 In order to maximise the likelihood of 
achieving separation between trial arms, the DRINK trial 
will employ several novel approaches that include home 
monitoring of uSG and the use of smartphone technology 
for both monitoring and direct feedback purposes. Given 
that these strategies will be combined with education and 
counselling and regular dietary review of solute intake, 
failure to achieve and maintain separation between arms 
using the DRINK trial design would cast serious doubt on 
the feasibility of a larger trial powered to detect effects on 
kidney function decline. Assessment of the potential for 
a biologically meaningful separation will be facilitated by 
the objective analysis of measured urine osmolality and 
plasma copeptin concentrations.
Figure 3 Calculation of fluid prescription using the free water clearance equation. Insensible losses were arbitrarily set at 
500 mL as an average.
Table 1 Advice given to participants based on urine SG 
and treatment group
Urine SG HW group advice AW group advice
1.005 Maintain Reduce intake by three 
cups
1.010 Maintain Reduce intake by two 
cups
1.015 Increase intake by two 
cups
Maintain
1.020 Increase intake by three 
cups
Maintain
1.025 Increase intake by four 
cups
Maintain
1.030 Increase intake by five 
cups
Maintain
AW, ad libitum water; HW, high water; SG, specific gravity. 
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Determinations
Blood pressure will be assessed after 5 min rest while 
seated. Screening blood pressure will be assessed using 
the DINAMAP Carescape monitor in routine clinic use. 
Blood pressure measurements will be taken in tripli-
cate, and the mean of the second and third measure-
ment reported. Brachial blood pressure will be taken in 
the non-dominant arm with an appropriately sized cuff, 
according to British Hypertension Society guidance. 
Side room urinalysis will be carried out using Siemens 
Multistix GP indicator strips, read by Siemens CliniTek 
Status+ auto-analyser. uSG will be measured as a surrogate 
for urine osmolality by automated analysis of colorimetric 
change on Siemens Multistix.
Home measurement will be conducted by visual assess-
ment of colorimetric change, read after 45 s against the 
manufacturer’s standard reference colour chart. Urine 
volume and measured urine osmolality will be obtained 
by performing two 24 hours urine collections at base-
line. Further 24 hours urine samples will be obtained at 
2, 8 and 12 weeks. Spot urine samples will be collected 
for urine osmolality estimation at every visit. Urine and 
plasma osmolality is measured on the Advanced Instru-
ments Micro-Osmometer, Model 3320 using the freezing 
point depression method.
Creatinine will be measured using the Siemens Advia 
2400 autoanalyser. Screening eGFR will be derived from 
the 4-variable MDRD GFR equation.22 All within-trial 
eGFR measurements will be calculated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation.23 Serum copeptin (a surrogate for vasopressin 
concentrations)24 will be analysed by the Department 
of Clinical Chemistry at the Royal Victoria Infirmary, 
Newcastle, UK.
Plasma samples will be obtained on all participants at 
all time points for biobanking.
Measured GFR will be determined by 51CR-EDTA. 
On the day preceding the test, participants will be 
asked to abstain from high protein meals and exces-
sive caffeine, and to abstain from caffeine consumption 
after 22:00 hours. They will be permitted a light break-
fast on the day of the test. An intravenous injection of 
2MBq 51CR-EDTA was administered via a 16G cannula. 
Venous blood (10 mL) will be drawn from the contralat-
eral arm at baseline, 2, 3 and 4 hours after the injection. 
Samples will be centrifuged for 15 min at 2000 rpm to 
allow plasma separation, and read using a Wizard2 2480 
gamma counter (PerkinElmer). The GFR will be derived 
from the area under the plasma clearance curve using the 
slope intercept method.
Health-related quality of life will be assessed using the 
EQ5D quality of life questionnaire, administered at base-
line and 8 weeks.
Secondary outcome data from the efficacy trial of 
tolvaptan suggests that the drug reduces the frequency 
of acute episodic pain in ADPKD.25 Although the mech-
anism for pain relief is unclear, it was partly explained by 
the reduced incidence of urinary tract infection, stones, 
and cyst rupture and haemorrhage. As HW intake is asso-
ciated with reduced incidences of urinary stones and 
infections in the general population26 and the increasing 
recognition of chronic pain in the condition,27 we have 
chosen to assess pain in DRINK. This will be assessed 
using a bespoke pain assessment tool to collect longitu-
dinal data on the nature, frequency and pattern of pain, 
and analgesic use (see online supplementary appendix 
I). To date, no questionnaires have been validated for the 
assessment of pain in ADPKD. We will employ two brief 
questionnaires, which are validated and widely used for 
a broad range of chronic pain disorders in the general 
population, which are Short-form Brief Pain Inventory28 
and McGill Pain Questionnaire.28 The questionnaire will 
be completed at baseline and week 8, but participants can 
also record any acute episodes of pain at any time during 
the study. This will be facilitated through provision of the 
pain assessment tool within the trial smartphone app. A 
separate paper will follow that describes the results and 
feasibility of use in the DRINK cohort.
An acceptability questionnaire, adapted from that used 
by Torres et al,7 will be administered at the end of the 
trial to determine the sustainability and acceptability of 
long-term adherence to the trial fluid intake prescription. 
All questionnaire-based assessments (EQ5D, pain, accept-
ability) can be completed on paper, via email or via smart-
phone app. The trial smartphone app has been developed 
in collaboration with FatFractile . The app will be used 
to record home uSG results, capture questionnaire data 
as described above, allow messaging and reminder func-
tionality and to direct participants to help and addi-
tional information if required (see online supplementary 
appendix II). In order to avoid contamination between 
trial arms, two distinct versions of the app were devel-
oped, each specific to one of the trial arms. Identification 
of the version of the app used by participants could be 
monitored centrally to avoid use of the incorrect version.
Run-in period
Eligible patients who are prescribed either diuretics or 
Tolvaptan will be allowed to enter a 2-week run-in period 
after enrolment during which these drugs will be with-
drawn. At the end of the run-in period, these partici-
pants will be reassessed to ensure that they still met the 
eligibility criteria before commencing the trial. Diuretics 
will only be withdrawn if the indication is hypertension, 
and which case alternative antihypertensives will be 
prescribed. Alternatives that would result in acute effects 
on GFR will be avoided (ACE inhibitors and angiotensin 
receptor blockers).
Participant timeline
The trial design is represented graphically in figure 1 and 
the schedule of events in table 2.
Screening
Patients who are potentially eligible will be invited for a 
screening visit. Screening will include a medical history 
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and a targeted ADPKD-related history that captures data 
on the timing and nature of the diagnosis, kidney size and 
function, and the presence of any complications such as 
pain, haemorrhage, nephrolithiasis or infections. Comor-
bidities and medications will be recorded. A full physical 
examination will be conducted that includes assessment 
of blood pressure. Indicator strip side room urinalysis will 
be performed. Blood analysis will include a full blood 
count, liver function tests, electrolytes and creatinine 
and paired serum and spot urine osmolalities. Partici-
pants that are deemed eligible will be provided with two 
24 hours urine collection bottles for return at the time 
of the baseline visit in order to measure osmolality and 
urine volume.
Baseline
Eligible participants who have provided informed 
consent will be randomised at the time of the baseline 
visit. A targeted physical examination to assess fluid 
status and vital signs will be conducted. Participants will 
be weighed, prescribed medications noted and blood 
and urine taken to measure electrolytes and creatinine, 
osmolality and urinalysis. A baseline quality of life EQ5D 
questionnaire will be completed. Participants will be 
Table 2 Schedule of enrolment, intervention and assessments
Study period 
Time point 
Recruitment Trial visits
W24†
Active Washout
W0 W2 W4 W8 W12
Enrolment 
  Screening X
  Informed consent X
  Randomisation X
Intervention 
  High water intake
  Ad libitum water intake
Assessment 
  Medical history X
  Medication review X X X X X X
  Physical examination X X X X X X
  Vital signs (blood pressure, pulse rate and 
oximetry)
X X X X X X
  Height X
  Weight X X X X X X
  Haematology (full blood count) X
  Biochemistry (urea, creatinine, electrolytes, 
serum osmolality)
X X X X X X
  Biochemistry (liver function and bone profile) X
  Measured GFR* X X X
  Urine SG X X X X X X
  Spot urine osmolality X X X X X X
  24 hours urine collection (volume and 
osmolality)
X X X X
  Home uSG monitoring‡ X X X X
  SPLASH monitoring X X X X
  Dietary assessment X X X X
  Pain questionnaire‡ X X
  Acceptability questionnaire‡ X X
  EQ5D‡ X X
*51Cr-EDTA measured GFR performed as part of a substudy in eight participants in the HW group.
†24 weeks prestudy recruitment period.
‡Recorded using the DRINK smartphone app.
GFR, glomerular filtration rate; uSG, urine specific gravity.
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instructed on how to conduct indicator strip uSG anal-
ysis, and asked to perform urinalysis twice weekly on 
Mondays and Thursdays between 16:00 and 20:00 hours. 
They will be assisted in installing the DRINK trial smart-
phone app on their smartphone, and will be provided 
with a tutorial on its use. This will allow input of home 
uSG measurements. Participants who do not own a 
smartphone will be required to telephone, email or text 
uSG results to the trial team. Finally, participants will be 
required to complete the DRINK trial pain assessment 
tool (see online supplementary appendix I).
Follow-up (weeks 2, 4, 8)
Participants will be recalled for follow-up visits after 2, 4 
and 8 weeks. During these visits, a physical examination 
will be carried out and weight and vital signs recorded. 
Blood and urine samples will be taken to measure electro-
lytes and creatinine, osmolality and urinalysis. Urine for 
24 hours urine osmolality will be collected at weeks 2 and 
8, respectively. A dietary assessment will be carried out at 
weeks 4 and 8. A pain assessment and EQ5D question-
naire will be completed at the 8-week visit.
Washout period and final visit
After completion of the intervention period (week 8), 
participants will be asked to revert to their pre-enrolment 
fluid intake. After a further 4 weeks, a final visit will be 
conducted (week 12). This will include all assessments 
conducted at the 8-week visit, with the exception of pain 
and quality of life questionnaires.
substudy A
Effect of high water intake on 51CR-EDTA GFR
Determining the acute effects of HW intake on GFR is a 
prerequisite to the definition of renal end points in any 
future trial.22 We will conduct a substudy to determine the 
acute effect of HW intake on 51CR-EDTA GFR, to allow a 
more rigorous assessment of GFR than that derived from 
estimation equations. Eight patients will be enrolled in 
this substudy, which will require a negative pregnancy test 
in addition to the eligibility criteria for the main trial.
Participants in substudy A will undergo 51CR-EDTA GFR 
measurement at baseline, week 2 and week 4 in addition 
to all other trial measurements.
substudy b
SPLASH smartphone fluid intake monitoring
Substudy B was designed to evaluate the feasibility and 
usability of a novel smartphone-based fluid intake moni-
toring device termed SPLASH.18 This Android-based app 
uses reusable near field communication (NFC) adhesive 
tags that attach to drink holders (glasses, cups or bottles). 
Tags are calibrated before use by measuring the drinks 
container volume (using a standard measuring jug) and 
programming the app accordingly. The app is activated 
by holding the phone near the NFC tag, allowing the user 
to select the volume consumed by identifying the corre-
sponding fraction of the container (eg, full, one-half, 
one-quarter, etc). Ad hoc consumption of fluids from 
uncalibrated drinks holders is captured using customised 
credit card or keyring NFC tags precalibrated for most 
drinking scenarios. The app also allows input of daily 
fluid intake targets and displays progress towards this. 
Given that the system is android-specific, android phones 
will be provided to substudy B participants on loan where 
required.
At least 10 participants will be enrolled in substudy B. 
Participants in both trial arms will be eligible for substudy 
B enrolment. Training in the use of the SPLASH system 
will be provided in person, through provision of written 
information, and via an online training video (https:// 
vimeo. com/ 208818645). Participants will be allowed 
to use the SPLASH system freely, but will be specifically 
required to use this for at least 24 hours at the time of 
the baseline, week 2 and week 8 visits (to coincide with 
measured 24 hours urine osmolality).
At the end of substudy B, participants will be inter-
viewed to provide qualitative data on their experience of 
using the SPLASH app.
Patient and public involvement
HW intake is an issue of great importance and was iden-
tified as a key research priority by patients with ADPKD. 
The DRINK trial was first proposed by the PKD Charity 
in 2015 and, facilitated by the Patient Led Research 
Hub. Patient coinvestigators have remained involved 
throughout the design and set-up, and are coapplicants 
on the awarded funding grants for the trial. The study 
design was presented at several PKD Charity information 
days, and patients have provided valuable feedback on 
the intervention and the use of smartphone apps.
The findings of the DRINK trial will be available to 
patients on the DRINK trial-specific and PKD websites. 
They will also be presented at the PKD information days 
that are run throughout the year by the charity.
Adverse events and safety
Adverse events will be assessed at each study visit. Addi-
tionally, a 24-hour trial participant helpline will be made 
available. Given the nature of the intervention, fluid 
retention, worsening hypertension and hyponatraemia 
are adverse events of special interest.
Participants will be withdrawn from the trial in the 
case of persistent hyponatraemia (<132 mmol/L on two 
consecutive samples), fluid retention defined by the 
presence of one of 1) pulmonary oedema, 2) significant 
lower limb swelling or 3) uncontrolled hypertension 
on two consecutive visits despite optimal antihyperten-
sive treatment (as judged by the responsible clinician). 
Participants will also be withdrawn for a decline in 
eGFR by ≥10 mL/min/1.73 m2 or 25% from baseline, 
confirmed on two consecutive samples at separate time 
points.
All adverse events will be recorded from the point of 
informed consent on the appropriate case report forms. 
All serious adverse events will be assessed by the chief 
investigator in terms of seriousness and causality and 
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reported to the sponsor in accordance with Good Clinical 
Practice (GCP) guidance.
sample size
Data from a small pilot study by Armo et al showed that 
using a low osmolar diet and HW intake, urine osmolality 
could be reduced from 426±193 to 258±147 (p=0.01) with 
a non-significant change in the control group.12 This is 
comparable to the reduction seen in the TEMPO3:4 trial 
(472–264 mOsm/kg), where 81% receiving Tolvaptan 
achieved a urine osmolality <300 mOsm/kg compared 
with 17% in the placebo group.29 In order to observe 
a benefit of HW intake on the rate of kidney function 
decline, we estimate that a comparable proportion of 
the HW intake group should achieve a urine osmolality 
consistent with vasopressin suppression. We estimate that 
28 participants would be required to detect 85% of the 
HW intervention group reaching their target urine osmo-
lality and 15% of controls achieving a urine osmolality less 
than the target threshold (99% power, two-sided α=0.05). 
Assuming a 15% dropout rate, the minimum required 
sample size is 30.
statistical analysis
Analysis of the primary and secondary outcomes of 
the trial will use the intention-to-treat principle. All 
randomised participants will be included in the final anal-
ysis within their treatment group allocation regardless of 
compliance, withdrawal or protocol deviations. Data will 
be analysed as proportions/percentages, mean±SD and 
with linear mixed-level modelling for repeated measures 
(uSG, renal function and blood pressure). For non-para-
metric data median with IQR (2th–75th) with minimum 
and maximum values will be reported as appropriate. We 
will be using a 95% CI and a significance level of ≤0.05. 
The analysis will be carried out using the STATA V.15, 
College Station TX.
We will perform a qualitative assessment of SPLASH 
looking at ease and acceptability of use through partici-
pant questionnaires and face-to-face interviews. We will 
also collect exploratory data on the validity of SPLASH 
as a potential fluid intake-monitoring device, comparing 
the app-based intake volumes recorded to the coinciding 
urine osmolality results of 24 hours collections.
Data management and monitoring
Data collection will be performed by trained local 
research staff at each of the trial visits in the form of case 
report forms. This will then be entered into the DRINK 
trial database, which is housed in the National Institute 
for Health Research-accredited Cambridge Clinical Trials 
Unit and supervised by the trial data manager. Data from 
the DRINK and SPLASH smartphone apps will be trans-
ferred securely to the N3 NHS Database, where it can be 
accessed securely via a specialised administration panel 
by members of the research team using an encrypted 
password.
The DRINK study will undergo monitoring for regula-
tory compliance in accordance with the GCP guidance via 
the trial steering committee, which independently moni-
tors progress and conduct of the trial and will also provide 
advice on the continuation, termination or amendments 
to the trial protocol. DRINK is sponsored by Cambridge 
University Hospital NHS Foundation Trust and will be 
subject to regular monitoring visits and audits.
DIsCussIon
The DRINK trial will address the key feasibility issues 
facing future definitive HW intake trials in ADPKD. 
Importantly, it will determine the recruitment potential 
especially given the uptake of Tolvaptan, the optimal 
renal end point and effect size, the randomisation 
strategy and demonstrate whether biological feasibility 
which is essential to any subsequent efficacy findings is 
achievable. Water as a disease-modifying intervention 
could revolutionise the management of ADPKD, by 
providing a low cost, widely available treatment option 
for those in low-income and middle-income countries, 
and those with early disease for whom it is essential to 
target cyst development early. Yet the early stage of their 
condition and lack of renal function decline makes it 
difficult to justify the use of medications with poten-
tially toxic side effects as the risk-benefit ratio in this 
group remains largely unknown.
EthICs AnD DIssEMInAtIon
DRINK opened to recruitment in September 2016, 
and the last study visit is anticipated to be April 2018. 
The primary and secondary outcomes results will be 
published in peer-reviewed journals, this will include a 
separate report on the use of smartphone technology in 
clinical trial design and the longitudinal ADPKD pain 
characteristics. A synopsis of the trial findings will also 
be made available to participants and the public through 
the trial-specific website and the PKD Charity. All the 
DRINK data will be shared through the Cambridge Data 
Repository.
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